Takeda Pharmaceutical Company Limited: 2026 Fiscal Year Summary
Business Context and Reporting Period
This summary covers the fiscal year ended March 31, 2026, as reported in Takeda's Form 20-F filed on June 17, 2026. Takeda is a global R&D-driven biopharmaceutical company focused on gastrointestinal and inflammation, neuroscience, oncology, plasma-derived therapies, and vaccines. The company operates in approximately 80 countries, with 90.4% of revenue generated outside Japan. The reporting period reflects a strategic transition, including the upcoming leadership change where Julie Kim is set to succeed Christophe Weber as CEO in June 2026.
Key Financial Metrics
| Metric | FY 2026 (JPY Billion) | FY 2025 (JPY Billion) | Change (AER) |
|---|---|---|---|
| Revenue | 4,505.7 | 4,581.6 | -1.7% |
| Operating Profit | 6.2 | 342.6 | -98.2% |
| Net Profit (Loss) | (152.1) | 108.1 | Turn to Loss |
| Core Operating Profit | 1,172.5 | 1,162.6 | +0.8% |
| Core Net Profit | 814.4 | 775.8 | +5.0% |
| Free Cash Flow | 865.4 | 856.4 | +1.0% |
| Total Debt (Bonds & Loans) | 4,881.8 | 4,515.3 | +8.1% |
| Cash & Equivalents | 595.1 | 385.1 | +54.5% |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 1.7% (AER) and 2.7% (CER). The decline was primarily driven by the Neuroscience segment (-26.8% AER), largely due to continued generic erosion of VYVANSE/ELVANSE (revenue dropped to JPY 203.2 billion from JPY 350.6 billion). Other segments, including Gastroenterology, Rare Diseases, and Oncology, saw revenue growth.
- Operating Profit Collapse: Reported operating profit plummeted to JPY 6.2 billion from JPY 342.6 billion. This was primarily caused by a JPY 403.5 billion provision for legal proceedings related to the AMITIZA antitrust litigation verdict in the U.S. Additionally, impairment losses increased by JPY 34.2 billion, including JPY 58.2 billion for discontinued cell therapy programs and JPY 31.9 billion for ALUNBRIG.
- Core Performance: Excluding non-recurring items, Core Operating Profit increased slightly by 0.8% (AER), indicating underlying operational stability despite the headline loss.
- Debt and Liquidity: Total debt increased to JPY 4.88 trillion due to new bond issuances (JPY 184 billion JPY bonds and USD 2.4 billion USD notes) to refinance maturing debt and commercial paper. However, cash and cash equivalents rose significantly to JPY 595.1 billion, resulting in a total liquidity position of JPY 1.29 trillion.
Guidance, Outlook, and Risks
- Leadership Transition: Christophe Weber will retire in June 2026, succeeded by Julie Kim. A new transformation program approved in March 2026 aims to streamline corporate functions, with expected restructuring expenses of JPY 170 billion in FY2027.
- Pipeline Highlights: Positive Phase 3 results were announced for zasocitinib (psoriasis), oveporexton (narcolepsy), and rusfertide (polycythemia vera). NDAs for oveporexton and rusfertide were accepted by the FDA with Priority Review.
- Regulatory and Pricing Risks:
- U.S. IRA: ENTYVIO was selected for Medicare price negotiations effective January 2028, which could materially impact future sales.
- Generic Competition: TRINTELLIX faces generic competition following patent expiration in December 2026. VYVANSE continues to face significant generic erosion.
- EU Pharma Package: A provisional agreement on the EU "Pharma Package" reached in December 2025 may shorten exclusivity periods and increase compliance burdens.
- Legal Contingencies: The AMITIZA antitrust verdict resulted in a JPY 403.5 billion provision. Takeda intends to appeal. Other ongoing matters include ACTOS economic loss cases and various product liability claims.
Key Facts for Investor Verification
- AMITIZA Litigation Impact: Verify the finality of the JPY 403.5 billion provision and the status of the appeal process, as this single item drove the reported net loss.
- VYVANSE Erosion Trajectory: Monitor the rate of revenue decline for VYVANSE/ELVANSE as generic competition intensifies, impacting the Neuroscience segment significantly.
- Core vs. Reported Metrics: Distinguish between reported GAAP results (heavily impacted by one-time legal and impairment charges) and Core Financial Measures, which show a 5.0% increase in Core Net Profit.
- Debt Refinancing: Confirm the terms and interest rates of the new USD and JPY bonds issued in mid-2025 and their impact on future interest expense.
- Restructuring Costs: Track the execution of the new transformation program and the anticipated JPY 170 billion in restructuring expenses for FY2027.